Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 15;59(8):1083-91.
doi: 10.1093/cid/ciu521. Epub 2014 Jul 16.

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea

Affiliations
Randomized Controlled Trial

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea

Robert D Kirkcaldy et al. Clin Infect Dis. .

Abstract

Background: Ceftriaxone is the foundation of currently recommended gonorrhea treatment. There is an urgent need for backup treatment options for patients with cephalosporin allergy or infections due to suspected cephalosporin-resistant Neisseria gonorrhoeae. We evaluated the efficacy and tolerability of 2 combinations of existing noncephalosporin antimicrobials for treatment of patients with urogenital gonorrhea.

Methods: We conducted a randomized, multisite, open-label, noncomparative trial in 5 outpatient sexually transmitted disease clinic sites in Alabama, California, Maryland, and Pennsylvania. Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally. The primary outcome was microbiological cure of urogenital infections (negative follow-up culture) at 10-17 days after treatment among 401 participants in the per protocol population.

Results: Microbiological cure was achieved by 100% (lower 1-sided exact 95% confidence interval [CI] bound, 98.5%) of 202 evaluable participants receiving gentamicin/azithromycin, and 99.5% (lower 1-sided exact 95% CI bound, 97.6%) of 199 evaluable participants receiving gemifloxacin/azithromycin. Gentamicin/azithromycin cured 10 of 10 pharyngeal infections and 1 of 1 rectal infection; gemifloxacin/azithromycin cured 15 of 15 pharyngeal and 5 of 5 rectal infections. Gastrointestinal adverse events were common in both arms.

Conclusions: Gentamicin/azithromycin and gemifloxacin/azithromycin were highly effective for treatment of urogenital gonorrhea. Gastrointestinal adverse events may limit routine use. These non-cephalosporin-based regimens may be useful alternative options for patients who cannot be treated with cephalosporin antimicrobials. Additional treatment options for gonorrhea are needed. Clinical Trials Registration. NCT00926796.

Keywords: Neisseria gonorrhoeae; azithromycin; gemifloxacin; gentamicin; gonorrhea treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flow diagram. aThree of these participants vomited within 1 hour of study drug administration. bNine of these participants vomited within 1 hour of study drug administration. cParticipants may have been discontinued from the per protocol analysis for >1 reason, but only the primary reason is listed. Abbreviation: ITT, intent-to-treat.

Comment in

Similar articles

Cited by

References

    1. Curran JW. Management of gonococcal pelvic inflammatory disease. Sex Transm Dis. 1979;6(2 suppl):174–80. - PubMed
    1. Watson RA. Gonorrhea and acute epididymitis. Mil Med. 1979;144:785–7. - PubMed
    1. World Health Organization. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. Available at: http://whqlibdoc.who.int/publications/2011/9789241502450_eng.pdf . Accessed 18 March 2013.
    1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2012. Available at: http://www.cdc.gov/std/stats12/default.htm . Accessed 25 April 2014.
    1. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187–93. - PubMed

Publication types

MeSH terms

Associated data